Register
Login:
Share:
Email Facebook Twitter


London South East - Oil & Gas Investor Evening: Malcy, Echo, Savannah, SDX
Paul Welch speaks at London South East's Oil & Gas Investor Evening


Synairgen Share Price (SNG)



Share Price Information for Synairgen (SNG)


Share Price: 16.75Bid: 16.50Ask: 17.00Change: 0.00 (0.00%)No Movement on Synairgen
Spread: 0.50Spread as %: 3.03%Open: 16.75High: 16.75Low: 16.50Yesterday’s Close: 16.75

Synairgen Plc Ord 1P

Synairgen is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
16.75
Share Price SpacerBid
16.50
Share Price SpacerAsk
17.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
14,000
Share Price SpacerOpen
16.75
Share Price SpacerHigh
16.75
Share Price SpacerLow
16.50
Share Price SpacerClose
16.75
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 109.32m £18.31m 10,000

52 Week High 26.50 52 Week High Date 4-JUL-2018
52 Week Low 10.50 52 Week Low Date 13-DEC-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
1 14,000 0 8.679 1.93 0.00 0.00


London South East Users info for Synairgen




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

19-Oct-18
10:18:09
16.50
14,000
Sell* 
16.50
17.00
2,310
Trade Type:
Ordinary

18-Oct-18
15:53:00
16.625
10,700
Sell* 
16.50
17.00
1,779
Trade Type:
Ordinary

18-Oct-18
08:01:25
16.90
20,000
Buy* 
16.00
17.00
3,380
Trade Type:
Ordinary




View more Synairgen trades >>

Directors Deals for Synairgen (SNG)
Trade DateActionNotifierPriceCurrencyAmountHolding
12-Oct-18Buy
Trade Notifier Information for Synairgen
Richard J Marsden held the position of CEO at Synairgen at the time of this trade.
 Richard J Marsden
16GBX156,250310682
12-Oct-18Buy
Trade Notifier Information for Synairgen
John C Ward held the position of Finance Director at Synairgen at the time of this trade.
 John C Ward
16GBX62,500339006
12-Oct-18Buy
Trade Notifier Information for Synairgen
Phillip David Monk held the position of Chief Scientific Officer at Synairgen at the time of this trade.
 Phillip David Monk
16GBX46,875230314
View more Synairgen directors dealings >>


cadburyhill
Posts: 421
Opinion:Strong Buy
Price:16.75
another chunky fibrosis deal
Thu 17:02
from today's Fiercebiotech.
"After having invested in Morphic Therapeutic’s A and B rounds, AbbVie is pulling the trigger on an R&D deal. The drugmaker is ponying up $100 million for the option to exclusively license multiple programs from Morphic that target fibrotic diseases.

Morphic’s pipeline consists of oral integrin inhibitors—integrin being a cell surface receptor found on most cells. Integrin signaling is involved in many cellular functions and abnormal signaling has been implicated in fibrosis, autoimmune diseases and immuno-oncology.

Under the agreement, Morphic will carry out R&D work on its fibrosis drugs through IND-enabling studies. At that point, AbbVie will be able to decide for each compound whether it will pay a license fee and then pick up responsibility for the global development and commercialization of the drug. Morphic could also bag clinical and commercial milestone payments and royalties for each drug that AbbVie takes forward.

Morphic also retains the option to share development costs with AbbVie on liver fibrosis indications, in exchange for “enhanced royalties.”

“Those liver markets are big,” said Morphic CEO Praveen Tipirneni, M.D. “With NASH, cirrhotic liver and so on ... we obviously had to have something pretty special to negotiate those kinds of rights.”
RichTheNewbie
Posts: 18,862
Opinion:No Opinion
Price:16.25
RNS
Mon 08:53
Leonard Licht still accumulating here (may have been during placing).
His stake up to nearly 10% now:
https://uk.advfn.com/stock-market/london/synairgen-SNG/share-news/Synairgen-plc-Holdings-in-Company/78458565
cadburyhill
Posts: 421
Opinion:No Opinion
Price:16.25
RE: Trading
12 Oct '18
Yes. The market maker knew it was good news. He/she collapsed the bid y’day afternoon to try and gather some scraps of stock to facilitate the buys we are now seeing....still, am surprised not to have seen an RNS this morn, not that we necessarily need it...
RichTheNewbie
Posts: 18,862
Opinion:No Opinion
Price:16.25
Trading
12 Oct '18
Looking like people held off purely due to market wobbles hoping for a drop but it didn't come. Large buys coming in now.
cadburyhill
Posts: 421
Opinion:Strong Buy
Price:15.55
RE: Pharmaxis trial results
11 Oct '18
Agreed....can only be matter of time till we see the formal release on this news.
i also completely agree with Rich. This is such a valuable therapeutic target area that the numbers could really surprise.

Final point: think we haven't see the last of Astra in respiratory...They've had set-backs in the alternative paths they chose over SNG001 a couple of years back. They know the quality of the output from this team..
View more share chat for Synairgen (SNG) >>




Synairgen Plc Ord 1P home pageWebsite: Synairgen Plc Ord 1P
Website Description: New Treatments for Respiratory Diseases - Synairgen Ltd



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.